pharmaphorum| News & views on pharma and biotech’s evolving future

News

First gene-edited pig liver transplant 'worked for 10 days'

In a xenotransplant milestone, scientists have carried out the first transplant of a genetically modified pig liver into a brain-dead human patient.

News

HHS plans 10,000 more job cuts, taking target to 20,000

HHS Secretary Kennedy has said he intends to save $1.8bn per year, thanks to another wave of job cuts affecting the FDA, CDC, NIH, and CMS.

R&D

Contraceptive pills condoms and intrauterine device Deep Dive feature

A tipping point for birth control: As barriers rise, is cont...

News

Alcon claims control of cell therapy firm Aurion

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive.

News

Jean-François Toussaint, Sanofi's global head of vaccines R&D

FDA fast-tracks Sanofi's experimental chlamydia vaccine

Sanofi is preparing to start human testing of its chlamydia vaccine, now fast-tracked by the FDA, that it hopes will be the first to reach the market.

Featured Content

Patients

The growing burden of misinformation: Patients left wonderin...

It’s no secret that challenges related to misinformation are rising, as more people rely on personalised news feeds and non-traditional information channels across the internet and social m

R&D

Deep Dive's research and development 2025 edition out now banner

Deep Dive: Research and Development 2025

Every breakthrough in medicine, every new treatment that changes lives, starts with research.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

R&D

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

Market Access

IRA updates and making sense of the chaos in Washington, wit...

R&D

Jennifer Schneider’s insights on immunotherapy at JP Morgan ...

Jonah Comstock caught up with Jennifer Schneider, CEO of Centauri Therapeutics, in San Francisco in January during the JP Morgan Healthcare Conference

R&D

Life Sciences Industry Report - Part 7

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

Newsletters and Deep Dive
digital magazine

Latest News

News

First gene-edited pig liver transplant 'worked for 10 days'

In a xenotransplant milestone, scientists have carried out the first transplant of a genetically modified pig liver into a brain-dead human patient.

News

HHS plans 10,000 more job cuts, taking target to 20,000

HHS Secretary Kennedy has said he intends to save $1.8bn per year, thanks to another wave of job cuts affecting the FDA, CDC, NIH, and CMS.

News

Alcon claims control of cell therapy firm Aurion

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive.

News

FDA fast-tracks Sanofi's experimental chlamydia vaccine

Sanofi is preparing to start human testing of its chlamydia vaccine, now fast-tracked by the FDA, that it hopes will be the first to reach the market.

Views & Analysis

Patients

The growing burden of misinformation: Patients left wonderin...

It’s no secret that challenges related to misinformation are rising, as more people rely on personalised news feeds and non-traditional information channels across the internet and social m

R&D

Jennifer Schneider’s insights on immunotherapy at JP Morgan ...

Jonah Comstock caught up with Jennifer Schneider, CEO of Centauri Therapeutics, in San Francisco in January during the JP Morgan Healthcare Conference

Market Access

5 ways to address pricing and access challenges across the E...

In the feature ‘Successfully navigating the complexity of market access across Europe to improve health equity’, originally published in the European Biopharmaceutical Review, EVERSANA Gene

Market Access

Boehringer US head talks GLP-1s, PBMs, Trump at Reuters USA

Brian Hilberdink, Boehringer Ingelheim's new Head of US Human Pharma, fielded questions on a variety of hot topics from the Reuters Pharma USA stage.

Deep Dive

R&D

R&D Contraceptive pills condoms and intrauterine device

Research and Development

R&D

A tipping point for birth control: As barriers rise, is cont...

R&D

A history of vaccination: How immunisation transformed publi...

R&D

Cheminformatics 101: The science behind smarter drug design

White Papers & Webinar

R&D

Life Sciences Industry Report - Part 7

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

R&D

Life Sciences Industry Report - Part 6

There are some 7,000 known rare diseases in the world, yet, multiple challenges and unmet needs remain when it comes to therapies for these diseases.

Oncology

Life Sciences Industry Report - Part 5

Developments in the oncology space in 2024 brought hope to both industry and patients.

R&D

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

Podcasts & Video

R&D

Jennifer Schneider’s insights on immunotherapy at JP Morgan ...

Jonah Comstock caught up with Jennifer Schneider, CEO of Centauri Therapeutics, in San Francisco in January during the JP Morgan Healthcare Conference

Digital